India, Aug. 21 -- Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in three presentations, including 1,000 mg/10 mL and 5,000 mg/50 mL single-dose vials and a 10,000 mg/100 mL pharmacy bulk package.
The products are bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi USA. According to IQVIA data, the US market for the product recorded annual sales of approximately USD 69.9 million for the 12 months ended June 2026.
The launch is expected to strengthen Glenmark's US injectables business and expand its hospital-focused portfolio.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....